Ashland

The potential of the mucoadhesive film technology is hard to ignore, owing to perceived superior patient acceptability versus buccal tablets, and significant...

Do you want to learn how to optimize immediate release formulations in terms of disintegration performance? Then register for our...

Abstract The disintegration time is critical for characterizing orally disintegrating tablets (ODTs), according to regulatory standards. The current study aimed...

WILMINGTON, Del., Oct. 31, 2022 -- Ashland Inc. (NYSE: ASH) today announced the United States Food and Drug Administration (FDA)...

CPHI worldwide opens its doors again. This year in Frankfurt at the Messe Frankfurt. In two weeks, from 1st to...

Purpose Whilst significant progress has been made to defeat HIV infection, the efficacy of antiretroviral (ARV) therapy in the paediatric...

Wilmington, Del., Oct. 3, 2022 Ashland is introducing Klucel™ xtend hydroxypropyl cellulose (HPC) controlled release matrix former, designed to deliver...

The pharmaceutical industry needs innovative, new and novel excipients solutions to support the developments in next generation therapeutics, new manufacturing...

The objective of this work was to optimize a thermosensitive in situ gelling formulation to improve intranasal and nose-to-brain delivery...

To manage early morning symptoms of nocturnal bronchial asthma, a chronotherapeutic drug delivery system (ChrDDS) of montelukast sodium was designed...